Phase I
Moderna Therapeutics is inching closer to becoming a commercial company and the company sees a potential blockbuster in an experimental treatment.
The first full business week of the new year began with plenty of clinical trial news. Here’s a look.
It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations.
Data show superior efficacy after four weeks of treatment and more rapid onset of action for CBP-201 compared with data from studies of current standard of care therapy for AD
Even with the holiday week, there was still some clinical trial news coming out. Here’s a look.
With the holidays, it’s not surprising that it was a quiet week for clinical trial news. Nonetheless, some companies did have clinical trial stories to report. Here’s a look.
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Topas Therapeutics GmbH announced that the first patient has been enrolled in a first-in-human Phase 1 trial evaluating TPM203 in patients with pemphigus vulgaris, an orphan autoimmune disease.
Vaccitech Ltd announced that its strategic collaboration with the Ludwig Institute for Cancer Research, Vaccitech Oncology Limited, has entered into a clinical partnership with Cancer Research UK to develop VOLT’s VTP-600 immunotherapy as a treatment option for patients with non-small cell lung cancer.
As Biogen stays in the hunt for an Alzheimer’s treatment with the recent presentation of data about aducanumab made at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) conference on December 5, it’s expanding its pipeline.
PRESS RELEASES